✦ LIBER ✦

Cyclical mastalgia: Premenstrual syndrome or recurrent pain disorder?

✍ Scribed by Ader, D. N.; Shriver, C. D.; Browne, M. W.

Book ID: 120070680
Publisher: Informa plc
Year: 1999
Tongue: English
Weight: 444 KB
Volume: 20
Category: Article
ISSN: 0167-482X
DOI: 10.3109/01674829909075596

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Premenstrual syndrome and premenstrual b

Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): Disorders of essential fatty acid (EFA) metabolism

✍ Horrobin, D.F.; Manku, M.S. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 901 KB

Bipolar Disorder and Premenstrual Syndro

Bipolar Disorder and Premenstrual Syndrome or Premenstrual Dysphoric Disorder Comorbidity: A Systematic Review

✍ Cirillo, Patricia Carvalho; Passos, Roberta Benitez Freitas; Bevilaqua, Mario Ce 📂 Article 📅 2012 🏛 SciELO 🌐 Portuguese ⚖ 681 KB

Cyclical or continuous treatment of the

Cyclical or continuous treatment of the premenstrual syndrome (PMS) with bromocriptine

✍ Ylöstalo, P. 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Cognitive-Behavioral and Pharmacological

Cognitive-Behavioral and Pharmacological Interventions for Premenstrual Syndrome or Premenstrual Dysphoric Disorder: A Meta-Analysis

✍ Maria Kleinstäuber, Michael Witthöft… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 292 KB

Psychiatric (axis I) and personality (ax

Psychiatric (axis I) and personality (axis II) disorders in patients with burning mouth syndrome or atypical facial pain

✍ Tero Taiminen; Laura Kuusalo; Laura Lehtinen; Heli Forssell; Nora Hagelberg; Oll 📂 Article 📅 2011 🏛 Walter de Gruyter GmbH 🌐 English ⚖ 134 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated